Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2025-06-13 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. This document provides the final results of a capital increase (rights offering), including subscription details, allocation results, and the use of proceeds. It is a standard regulatory filing for companies that have completed a public offering of securities. Among the provided categories, 'SHA' (Share Issue/Capital Change) is the most accurate fit as it specifically covers announcements regarding new share issues and capital changes.
2025-06-13 Korean
유상증자또는주식관련사채등의청약결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Cha Biotech regarding the results of a paid-in capital increase (rights offering). It details the subscription results, including the number of shares subscribed, the subscription rate, and the handling of fractional shares. This falls under the category of share issuance and capital changes, specifically reporting the outcome of a capital increase event.
2025-06-09 Korean
유상증자최종발행가액확정
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Cha Biotech regarding the final determination of the issue price for a paid-in capital increase (rights offering). It details the calculation methodology for the issue price, the final price per share, and the number of shares to be issued. This falls under the category of capital structure changes and financing activities, specifically related to share issuance.
2025-05-30 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Capital Increase Decision' (유상증자결정) for Cha Biotech. It details the amendment of the issuance price for a rights offering, including specific pricing formulas, subscription dates, and allocation methods. This falls under the category of announcements regarding new share issues or capital changes.
2025-05-30 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 98% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of issuance terms (발행조건확정) for a capital increase (유상증자). This type of filing is a regulatory requirement for companies raising capital through public offerings or rights issues. It is not a simple announcement (RPA) but the formal regulatory filing itself, which falls under the 'Regulatory Filings' category as it is a specific legal document for securities registration.
2025-05-30 Korean
[기재정정]투자설명서
Investor Presentation Classification · 98% confidence The document is a 'Investment Prospectus' (투자설명서) amendment (정정신고) filed by 'Cha Biotech' (차바이오텍). It details updates to the prospectus, including the reflection of Q1 2025 financial results and the finalization of the offering price for a capital raise (share issuance). In the context of Korean regulatory filings (DART), this is a formal 'Securities Registration Statement' (증권신고서) amendment, which falls under the category of capital/financing updates.
2025-05-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.